S&P/ASX 200 dives 2.53% as AstraZeneca pauses COVID-19 vaccine trial; oil tumbles 7.6%

Credit: Proactive Investors- Published on September 9, 2020
S&P/ASX 200 (INDEXASX:XJO) fell 2.53% to 5,856 by 1.15 pm as a phase 3 clinical study testing a potential COVID-19 vaccine developed by the University of Oxford was temporarily put on hold after a volunteer had an adverse reaction. British pharmaceutical company AstraZeneca (LON:AZN), which is developing the vaccine alongside...

You are here

Related videos from verified sources

Daily Covid-19 Minute: Astrazenecaโ€™s Vaccine Trial Has Been On Pause For 6 Weeks, Hereโ€™s What We Know 01:08
Credit: CBS 62 Detroit - Published 3 days ago 

AstraZeneca Covid-19 Vaccine Trial Showing Promising Results 02:03
Credit: The Street - Published 4 days ago 

J&J, AstraZeneca resuming trials of vaccines 01:08
Credit: Reuters Studio - Published 5 days ago 

You might like